Key Takeaway: Precision BioSciences has reported its fourth quarter and fiscal year 2024 financial results, highlighting significant advancements in its gene editing programs. Notably, the company announced the first in vivo clinical validation for its ARCUS gene editing technology across two programs. Additionally, the Phase 1 ELIMINATE-B clinical trial for PBGENE-HBV has commenced, marking a milestone in Hepatitis B treatment.
Price reaction · baseline $5.09 (2025-03-25 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
-11%
day 1
-10.8%
day 3
-6.3%
Market Sentiment Analysis
POSITIVE FACTORS
First in vivo clinical validation for ARCUS gene editing announced.
Commenced Phase 1 ELIMINATE-B clinical trial for PBGENE-HBV.
PBGENE-HBV is the first gene editing technology studied for Hepatitis B.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Announced first in vivo clinical validation for ARCUS gene editing across two distinct programs including wholly owned PBGENE-HBV and partnered program ECUR-506 – – Commenced Phase 1 ELIMINATE-B clinical trial for PBGENE-HBV, the first gene editing technology studied for Hepatitis B, in fourth
Frequently Asked Questions
What were the key highlights from Precision BioSciences' Q4 report?
The report highlighted the first in vivo clinical validation for ARCUS gene editing and the commencement of the Phase 1 ELIMINATE-B trial for PBGENE-HBV.
What is the significance of the PBGENE-HBV trial?
PBGENE-HBV is the first gene editing technology being studied for Hepatitis B, marking a significant advancement in treatment options.
What programs were validated in the report?
The report announced clinical validation for ARCUS gene editing across two programs, including PBGENE-HBV and ECUR-506.